护理人员对基于血液的阿尔茨海默病生物标志物测试的态度
Katharina Bolsewig1, Hester Blok2, Eline A J Willemse1,3
1Department of Laboratory Medicine Neurochemistry Laboratory Amsterdam Neuroscience Amsterdam UMC VU University Amsterdam the Netherlands.
Alzheimer's & dementia (Amsterdam, Netherlands)
|February 19, 2024
概括
大多数非正式的护理人员支持基于血液的生物标志物 (BBBM) 测试来诊断阿尔茨海默病 (AD). 随着治疗的可用性和耻辱感的减少,人们的兴趣会增加,尽管随着症状的严重性,人们的信心会下降.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 非正式的护理人员在阿尔茨海默病 (AD) 患者护理中发挥着至关重要的作用.
- 了解护理人员对诊断工具的看法对于实施至关重要.
- 基于血液的生物标志物 (BBBM) 为AD诊断提供了一个有前途的途径.
研究的目的:
- 评估非正式护理人员对接受和实施阿尔茨海默病 (AD) 血液基生物标志物 (BBBM) 测试的态度.
- 探索护理人员的担忧和与ADBBM测试相关的感知益处.
- 确定影响护理人员接受BBBM用于AD诊断和查的因素.
主要方法:
- 一种混合方法的方法,结合了在线调查 (n=107) 和焦点小组 (n=7) 与非正式的护理人员.
- 用描述性统计数据来分析定量调查数据.
- 专题内容分析应用于来自开放式调查问题和重点小组的定性数据.
主要成果:
- 大多数护理人员 (72.0%) 赞成BBBM测试用于AD诊断.
- 对正常BBM结果的信心随着症状严重程度的下降 (轻度:78.5%vs重度:48.6%).
- 对BBBM进行查的兴趣随着治疗的前景 (53.3%对92.5%) 显著增加,包括治疗不可用性和耻辱感.
结论:
- 新兴的AD治疗方法和减少耻辱感可能会大大提高公众对BBBM测试的兴趣.
- 护理人员接受BBBM测试受到感知可操作性,更好的护理潜力和未来治疗选择的影响.
- 解决护理人员对痛苦,耻辱和治疗可用性的担忧对于成功实施BBBBM至关重要.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189


